Went on Threadguy, pitched Biotech (ARKG) long vs Google. Double digit outperformance since then. Took off Google short and rotated into MSFT CRM shorts due to googles new model
"The one fund in the top 20 that isn't tied to energy, crypto or chips is the ARK Genomic Revolution ETF (ARKG), up 87%. Biotech has had a strong year, fueled by a wave of dealmaking and positive clinical data, and ARKG's concentrated portfolio of smaller genomics companies has amplified that rally."
- Sumit Roy,
Learn about ARKG:
Cathie Wood’s Ark Invest made several notable portfolio moves Tuesday, led by a major purchase of Rocket Lab ($RKLB) shares. Ark bought 292,873 shares across ARKK, ARKQ and ARKX, worth about $23.4 million.
Rocket Lab closed at $80.01 following a mixed second-quarter earnings report. The company posted a slightly wider-than-expected loss but beat revenue estimates and reported a record backlog of $2.36 billion.
Ark also increased its position in Cloudflare ($NET), purchasing 7,561 shares worth roughly $2.3 million. The stock closed at $306.97 as investors continued digesting the company’s strong quarterly results.
Cloudflare reported earnings of $0.29 per share, beating expectations of $0.27. Revenue reached $696.06 million, topping estimates, while CEO Matthew Prince highlighted record customer growth and raised the company’s fiscal 2026 outlook.
The trades suggest Ark remains confident in both commercial space and cloud infrastructure as long-term growth themes. Rocket Lab offers exposure to launch and space systems, while Cloudflare benefits from rising demand for internet infrastructure and cybersecurity services.
Ark also reduced several positions during the session. The firm sold shares of Deere ($DE), Shopify ($SHOP) and Caterpillar ($CAT) across multiple ETFs.
On the buying side, Ark added shares of Schrödinger ($SDGR) and Intellia Therapeutics ($NTLA) through ARKG. The moves reflect Ark’s continued strategy of shifting capital toward high-growth technology, space and biotechnology companies.